Lotus Pharmaceutical Co., Ltd. 1795.TW Stock
Lotus Pharmaceutical Co., Ltd. Price Chart
Lotus Pharmaceutical Co., Ltd. 1795.TW Financial and Trading Overview
| Lotus Pharmaceutical Co., Ltd. stock price | 332.5 TWD |
| Previous Close | 330 TWD |
| Open | 332.5 TWD |
| Bid | 322.5 TWD x N/A |
| Ask | 323 TWD x N/A |
| Day's Range | 321 - 334.5 TWD |
| 52 Week Range | 128 - 349.5 TWD |
| Volume | 9.19M TWD |
| Avg. Volume | 10.01M TWD |
| Market Cap | 84.64B TWD |
| Beta (5Y Monthly) | 0.575342 |
| PE Ratio (TTM) | 21.376572 |
| EPS (TTM) | 15.66 TWD |
| Forward Dividend & Yield | 1.93 (0.61%) |
| Ex-Dividend Date | August 4, 2022 |
| 1y Target Est | 326.4 TWD |
1795.TW Valuation Measures
| Enterprise Value | 95.59B TWD |
| Trailing P/E | 21.376572 |
| Forward P/E | 15.702479 |
| PEG Ratio (5 yr expected) | N/A |
| Price/Sales (ttm) | 5.291522 |
| Price/Book (mrq) | 6.0105324 |
| Enterprise Value/Revenue | 5.976 |
| Enterprise Value/EBITDA | 15.368 |
Trading Information
Lotus Pharmaceutical Co., Ltd. Stock Price History
| Beta (5Y Monthly) | 0.575342 |
| 52-Week Change | 125.25% |
| S&P500 52-Week Change | 20.43% |
| 52 Week High | 349.5 TWD |
| 52 Week Low | 128 TWD |
| 50-Day Moving Average | 293.94 TWD |
| 200-Day Moving Average | 236.87 TWD |
1795.TW Share Statistics
| Avg. Volume (3 month) | 10.01M TWD |
| Avg. Daily Volume (10-Days) | 7.09M TWD |
| Shares Outstanding | 262.04M |
| Float | 103.5M |
| Short Ratio | N/A |
| % Held by Insiders | 61.56% |
| % Held by Institutions | 7.90% |
| Shares Short | N/A |
| Short % of Float | N/A |
| Short % of Shares Outstanding | N/A |
Dividends & Splits
| Trailing Annual Dividend Rate | 3.46 |
| Trailing Annual Dividend Yield | 1.04% |
| 5 Year Average Dividend Yield | N/A |
| Payout Ratio | 0.13430001 |
| Last Split Factor | 1060:1000 |
Financial Highlights
Fiscal Year
| Fiscal Year Ends | December 31, 2022 |
| Most Recent Quarter (mrq) | March 31, 2023 |
| Next Fiscal Year End | December 31, 2023 |
Profitability
| Profit Margin | 23.56% |
| Operating Margin (ttm) | 33.07% |
| Gross Margin | 57.16% |
| EBITDA Margin | 38.88% |
Management Effectiveness
| Return on Assets (ttm) | 12.11% |
| Return on Equity (ttm) | 29.38% |
Income Statement
| Revenue (ttm) | 16B TWD |
| Revenue Per Share (ttm) | 61.34 TWD |
| Quarterly Revenue Growth (yoy) | 43.10% |
| Gross Profit (ttm) | 7.81B TWD |
| EBITDA | 6.22B TWD |
| Net Income Avi to Common (ttm) | 3.77B TWD |
| Diluted EPS (ttm) | 15.11 |
| Quarterly Earnings Growth (yoy) | 167.59% |
Balance Sheet
| Total Cash (mrq) | 1.66B TWD |
| Total Cash Per Share (mrq) | 6.35 TWD |
| Total Debt (mrq) | 10.78B TWD |
| Total Debt/Equity (mrq) | 76.55 TWD |
| Current Ratio (mrq) | 2.077 |
| Book Value Per Share (mrq) | 53.739 |
Cash Flow Statement
| Operating Cash Flow (ttm) | 3.25B TWD |
| Levered Free Cash Flow (ttm) | -1440644864 TWD |
Profile of Lotus Pharmaceutical Co., Ltd.
| Country | Taiwan |
| State | N/A |
| City | Taipei |
| Address | No. 277 Song Ren Road |
| ZIP | 110 |
| Phone | 886 2 2700 5908 |
| Website | https://www.lotuspharm.com.tw |
| Industry | Drug Manufacturers-Specialty & Generic |
| Sector(s) | Healthcare |
| Full Time Employees | N/A |
Lotus Pharmaceutical Co., Ltd. research, develops, manufactures, and sells generic pharmaceutical products in Taiwan, Korea, the United States, and internationally. Its product portfolio focuses on generics in the fields of oncology, cardiology, nephrology, women's health, anti-obesity, and central nervous system disease. The company also sells and markets a portfolio of over-the-counter medicines. In addition, it engages in wholesale of cosmetics; retail of clinical machines; biotech technological consulting services; sale of pharmaceuticals and medicinal chemical; marketing activities; market planning and business information services; and consultancy services on health management, health technology, and trading information services. Further, the company offers pharmaceutical regulatory affairs project management, and data collection and agency services; healthcare consultancy services and operates as a contract research organization. The company has an agreement with NeuroRx Inc. to develop, manufacture, and commercialize NRX-101. Lotus Pharmaceutical Co., Ltd. was incorporated in 1966 and is headquartered in Taipei City, Taiwan. Lotus Pharmaceutical Co., Ltd. is a subsidiary of Alvogen Emerging Markets Holdings Limited.
Q&A For Lotus Pharmaceutical Co., Ltd. Stock
What is a current 1795.TW stock price?
Lotus Pharmaceutical Co., Ltd. 1795.TW stock price today per share is 332.5 TWD.
How to purchase Lotus Pharmaceutical Co., Ltd. stock?
You can buy 1795.TW shares on the Taiwan exchange. Contact your financial advisor to select a broker.
What is the ticker symbol for Lotus Pharmaceutical Co., Ltd.?
The stock symbol or ticker of Lotus Pharmaceutical Co., Ltd. is 1795.TW.
Which industry does the Lotus Pharmaceutical Co., Ltd. company belong to?
The Lotus Pharmaceutical Co., Ltd. industry is Drug Manufacturers-Specialty & Generic.
How many shares does Lotus Pharmaceutical Co., Ltd. have in circulation?
The max supply of Lotus Pharmaceutical Co., Ltd. shares is 264.47M.
What is Lotus Pharmaceutical Co., Ltd. Price to Earnings Ratio (PE Ratio)?
Lotus Pharmaceutical Co., Ltd. PE Ratio is 21.23243900 now.
What was Lotus Pharmaceutical Co., Ltd. earnings per share over the trailing 12 months (TTM)?
Lotus Pharmaceutical Co., Ltd. EPS is 15.66 TWD over the trailing 12 months.
Which sector does the Lotus Pharmaceutical Co., Ltd. company belong to?
The Lotus Pharmaceutical Co., Ltd. sector is Healthcare.
Lotus Pharmaceutical Co., Ltd. 1795.TW included in indexes
| Name Name | Price Price |
24h% 7d chart 24h% & 7d |
VOL Volume | 24h low | 24h high | Volume |
|---|
| Name Name | Price Price |
24h% 7d chart 24h% & 7d |
VOL Volume | 24h low | 24h high | Volume | |
|---|---|---|---|---|---|---|---|
| {{ item.name }} {{ item.symbol }} | {{ item.price }} {{ item.price_usd }} |
{{ item.change_pct }}
|
{{ item.volume }} {{ item.volume_usd }} | {{ item.low }} {{ item.low_usd }} | {{ item.high }} {{ item.high_usd }} | {{ item.components_count }} - | {{ item.volume }} {{ item.volume_usd }} |
| Nasdaq EM Plus Korea Small Cap NQEMKRSCGBP | 1476.35 GBP 1888.16 USD |
<0.01
|
— — | 1476.35 GBP 1888.16 USD | 1476.35 GBP 1888.16 USD | — - | — — |
- {{ link.label }} {{link}}